Hormone therapy in the form of testosterone suppression is employed to shrink tumors and extend patient survival; however, once the cancer cells have been desensitized to AR stimulation and the cancer has evolved into metastatic castrate-resistant prostate cancer (mCRPC), hormone therapy is ineffective [2]. The gene discussed is AR; the disease is cancer.